1. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727–741.
2. al-Shabanah, O. A., Badary, O. A., Nagi, M. N., al-Gharably, N. M., al-Rikabi, A. C., & al-Bekairi, A. M. (1998). Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. Journal of Experimental and Clinical Cancer Research, 17, 193–198.
3. Bodley, A., Liu, L. F., Israel, M., Seshadri, R., Koseki, Y., Giuliani, F. C., Kirschenbaum, S., Silber, R., & Potmesil, M. (1989). DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Research, 49, 5969–5978.
4. Mettler, F. P., Young, D. M., & Ward, J. M. (1977). Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Research, 37, 2705–2713.
5. Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L. Jr., Von Hoff, A. L., Rozencweig, M., & Muggia, F. M. (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710–717.